EDITORIAL
Aspirin use in essential thrombocythemia: Once-daily or twice-daily or not at all?
Ayalew Tefferi,
Tiziano Barbui,
Corresponding Author
Ayalew Tefferi
Division of Hematology, Department of Medicine, Mayo Clinic, Rochester, Minnesota, USA
Correspondence
Ayalew Tefferi, Division of Hematology, Department of Medicine, Mayo Clinic, 200 First St SW, Rochester, MN 55905, USA.
Email: [email protected]
Search for more papers by this authorTiziano Barbui
FROM Research Foundation, Papa Giovanni XXIII Hospital, Bergamo, Italy
Search for more papers by this authorAyalew Tefferi,
Tiziano Barbui,
Corresponding Author
Ayalew Tefferi
Division of Hematology, Department of Medicine, Mayo Clinic, Rochester, Minnesota, USA
Correspondence
Ayalew Tefferi, Division of Hematology, Department of Medicine, Mayo Clinic, 200 First St SW, Rochester, MN 55905, USA.
Email: [email protected]
Search for more papers by this authorTiziano Barbui
FROM Research Foundation, Papa Giovanni XXIII Hospital, Bergamo, Italy
Search for more papers by this authorGraphical Abstract
Asprin dosing strategy in low risk (young and JAK2 mutated without history of thrombosis) or very low risk (young JAK2 wild-type without history of thrombosis) essential thrombocythemia.
CONFLICT OF INTEREST STATEMENT
None of the authors have any conflict of interest regarding the current manuscript.
Open Research
DATA AVAILABILITY STATEMENT
By email to the corresponding author.
REFERENCES
- 1Arber DA, Orazi A, Hasserjian RP, et al. International consensus classification of myeloid neoplasms and acute Leukemias: integrating morphologic, clinical, and genomic data. Blood. 2022; 140: 1200-1228.
- 2Szuber N, Vallapureddy RR, Penna D, et al. Myeloproliferative neoplasms in the young: Mayo Clinic experience with 361 patients age 40 years or younger. Am J Hematol. 2018; 93: 1474-1484.
- 3Mesa RA, Silverstein MN, Jacobsen SJ, Wollan PC, Tefferi A. Population-based incidence and survival figures in essential thrombocythemia and agnogenic myeloid metaplasia: an Olmsted County study, 1976-1995. Am J Hematol. 1999; 61: 10-15.
10.1002/(SICI)1096-8652(199905)61:1<10::AID-AJH3>3.0.CO;2-I CAS PubMed Web of Science® Google Scholar
- 4Tefferi A, Guglielmelli P, Larson DR, et al. Long-term survival and blast transformation in molecularly annotated essential thrombocythemia, polycythemia vera, and myelofibrosis. Blood. 2014; 124(16): 2507-2513.
- 5Szuber N, Mudireddy M, Nicolosi M, et al. 3023 Mayo Clinic patients with myeloproliferative neoplasms: risk-stratified comparison of survival and outcomes data among disease subgroups. Mayo Clin Proc. 2019; 94: 599-610.
- 6Hultcrantz M, Kristinsson SY, Andersson TM, et al. Patterns of survival among patients with myeloproliferative neoplasms diagnosed in Sweden from 1973 to 2008: a population-based study. J Clin Oncol. 2012; 30: 2995-3001.
- 7Barosi G, Mesa RA, Thiele J, et al. Proposed criteria for the diagnosis of post-polycythemia vera and post-essential thrombocythemia myelofibrosis: a consensus statement from the international working Group for Myelofibrosis Research and Treatment. Leukemia. 2008; 22: 437-438.
- 8Tefferi A, Alkhateeb H, Gangat N. Blast phase myeloproliferative neoplasm: contemporary review and 2024 treatment algorithm. Blood Cancer J. 2023; 13: 108.
- 9Gangat N, Karrar O, Al-Kali A, et al. One thousand patients with essential thrombocythemia: the Mayo Clinic experience. Blood Cancer J. 2024; 14: 11.
- 10Loscocco GG, Gesullo F, Capecchi G, et al. One thousand patients with essential thrombocythemia: the Florence-CRIMM experience. Blood Cancer J. 2024; 14: 10.
- 11Tefferi A, Vannucchi AM, Barbui T. Essential thrombocythemia: 2024 update on diagnosis, risk stratification, and management. Am J Hematol. 2024; 99: 697-718.
- 12Cortelazzo S, Finazzi G, Ruggeri M, et al. Hydroxyurea for patients with essential thrombocythemia and a high risk of thrombosis. N Engl J Med. 1995; 332: 1132-1136.
- 13Landolfi R, Marchioli R, Kutti J, et al. Efficacy and safety of low-dose aspirin in polycythemia vera. N Engl J Med. 2004; 350: 114-124.
- 14Godfrey AL, Campbell PJ, MacLean C, et al. Hydroxycarbamide plus aspirin versus aspirin alone in patients with essential Thrombocythemia age 40 to 59 years without high-risk features. J Clin Oncol. 2018; 36: 3361-3369.
- 15Harrison CN, Campbell PJ, Buck G, et al. Hydroxyurea compared with anagrelide in high-risk essential thrombocythemia. N Engl J Med. 2005; 353: 33-45.
- 16Gisslinger H, Gotic M, Holowiecki J, et al. Anagrelide compared with hydroxyurea in WHO-classified essential thrombocythemia: the ANAHYDRET study, a randomized controlled trial. Blood. 2013; 121: 1720-1728.
- 17Mascarenhas J, Kosiorek HE, Prchal JT, et al. A randomized phase 3 trial of interferon-alpha vs hydroxyurea in polycythemia vera and essential thrombocythemia. Blood. 2022; 139: 2931-2941.
- 18Tartaglia AP, Goldberg JD, Berk PD, et al. Adverse effects of antiaggregating platelet therapy in the treatment of polycythemia vera. Semin Hematol. 1986; 23: 172-176.
- 19Masotti G, Galanti G, Poggesi L, Abbate R, Neri Serneri GG. Differential inhibition of prostacyclin production and platelet aggregation by aspirin. Lancet. 1979; 2: 1213-1217.
- 20Scavone M, Rizzo J, Femia EA, et al. Patients with essential Thrombocythemia may be poor responders to enteric-coated aspirin, but not to plain aspirin. Thromb Haemost. 2020; 120: 1442-1453.
- 21Cattaneo M. Aspirin in essential thrombocythemia. For whom? What formulation? What regimen? Haematologica. 2023; 108: 1487-1499.
- 22Rocca B, Tosetto A, Petrucci G, et al. Long-term pharmacodynamic and clinical effects of twice- versus once-daily low-dose aspirin in essential thrombocythemia: the ARES trial. Am. J. Hematol. 2024; 99: 1462-1475.
- 23Barbui T, Finazzi G, Carobbio A, et al. Development and validation of an international prognostic score of thrombosis in World Health Organization-essential thrombocythemia (IPSET-thrombosis). Blood. 2012; 120: 5128-5133.
- 24Rocca B, Tosetto A, Betti S, et al. A randomized double-blind trial of 3 aspirin regimens to optimize antiplatelet therapy in essential thrombocythemia. Blood. 2020; 136: 171-182.
- 25Perez Encinas MM, Sobas M, Gomez-Casares MT, et al. The risk of thrombosis in essential thrombocythemia is associated with the type of CALR mutation: a multicentre collaborative study. Eur J Haematol. 2021; 106: 371-379.
- 26Alvarez-Larran A, Pereira A, Guglielmelli P, et al. Antiplatelet therapy versus observation in low-risk essential thrombocythemia with a CALR mutation. Haematologica. 2016; 101: 926-931.
- 27Alvarez-Larran A, Cervantes F, Pereira A, et al. Observation versus antiplatelet therapy as primary prophylaxis for thrombosis in low-risk essential thrombocythemia. Blood. 2010; 116: 1205-1210.
- 28Liu W, Pircher J, Schuermans A, et al. Jak2 V617F clonal hematopoiesis promotes arterial thrombosis via platelet activation and cross talk. Blood. 2024; 143: 1539-1550.
- 29Petrucci G, Giaretta A, Ranalli P, et al. Platelet thromboxane inhibition by low-dose aspirin in polycythemia vera: ex vivo and in vivo measurements and in silico simulation. Clin Transl Sci. 2022; 15: 2958-2970.
- 30Mainoli B, Duarte GS, Costa J, Ferreira J, Caldeira D. Once- versus twice-daily aspirin in patients at high risk of thrombotic events: systematic review and meta-analysis. Am J Cardiovasc Drugs. 2021; 21: 63-71.
- 31Wegerif ECJ, Unlu C, Generaal MI, et al. Rationale and design for the randomized placebo-controlled double-blind trial studying the effect of single antiplatelet therapy (clopidogrel) versus dual antiplatelet therapy (clopidogrel/acetylsalicylic acid) on the occurrence of atherothrombotic events following lower extremity peripheral transluminal angioplasty (CLEAR-PATH). Am Heart J. 2024; 273: 121-129.
Citing Literature
